Health products policy and standards
Our team provides authoritative guidance and standards on quality, safety and efficacy of health products and supports countries to formulate evidence-based policies and ensure good practice throughout the value chain.
/health-product-policy-and-standards-(hps)/63022.jpg?sfvrsn=e93c78d1_9 "Ministry of Health staff at their office in Port Vila")
/health-product-policy-and-standards-(hps)/who_034416-sm.jpg?sfvrsn=fc08f9ca_4 "WHO_034416 sm")
/health-product-policy-and-standards-(hps)/70820.jpg?sfvrsn=6b0fda4c_1 "70820")
Expert Committees
Advisory groups
Databases
Publications
All →
23 September 2025
Availability, price and affordability of health technologies for the management of diabetes
The WHO list of priority medical devices for management of cardiovascular diseases and diabetes, https://iris.who.int/handle/10665/341967, describes those...
5 September 2025
The selection and use of essential medicines, 2025: WHO AWaRe (Access, Watch, Reserve) classification...
The AWaRe classification is intended as a tool for monitoring antibiotic use, defining targets and monitoring the impact of stewardship policies and interventions...
5 September 2025
The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines for Children,...
Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and...
5 September 2025
The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list
Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and...
Journal articles
The “Square Box”: Therapeutic Equivalence as a Foundation of the WHO Model List of Essential Medicines
Front Pharmacol. 2020 Sep 11;11:578000
WHO's essential medicines and AWaRe: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections
Clinical Microbiology and Infection 30 (2024) S1eS51
Identifying and costing common gaps in Central and West Africa pharmaceutical regulation
Front. Med., 05 April 2024 Sec. Regulatory Science
